CANF
Price:
$2.32
Market Cap:
$14.14M
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops ...[Read more]
Industry
Biotechnology
IPO Date
2012-11-06
Stock Exchange
AMEX
Ticker
CANF
According to Can-Fite BioPharma Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.89. This represents a change of -39.08% compared to the average of -1.46 of the last 4 quarters.
The mean historical PE Ratio of Can-Fite BioPharma Ltd. over the last ten years is -774.06. The current -0.89 PE Ratio has changed -88.50% with respect to the historical average. Over the past ten years (40 quarters), CANF's PE Ratio was at its highest in in the December 2015 quarter at 11.17K. The PE Ratio was at its lowest in in the September 2018 quarter at -10969.67.
Average
-774.06
Median
-560.41
Minimum
-2095.76
Maximum
-0.72
Discovering the peaks and valleys of Can-Fite BioPharma Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 98.37%
Maximum Annual PE Ratio = -0.72
Minimum Annual Increase = -99.94%
Minimum Annual PE Ratio = -2095.76
Year | PE Ratio | Change |
---|---|---|
2023 | -1.23 | -24.59% |
2022 | -1.63 | -13.76% |
2021 | -1.89 | 31.47% |
2020 | -1.44 | 98.37% |
2019 | -0.72 | -99.94% |
2018 | -1118.93 | -29.00% |
2017 | -1575.97 | 9.95% |
2016 | -1433.31 | -31.61% |
2015 | -2095.76 | 38.82% |
2014 | -1509.69 | 1.87% |
The current PE Ratio of Can-Fite BioPharma Ltd. (CANF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.58
5-year avg
-1.38
10-year avg
-774.06
Can-Fite BioPharma Ltd.’s PE Ratio is greater than ImmuCell Corporation (-7.70), greater than Compugen Ltd. (-17.19), less than Evogene Ltd. (-0.76), greater than CollPlant Biotechnologies Ltd. (-3.36), greater than Protalix BioTherapeutics, Inc. (-4.99), greater than Corvus Pharmaceuticals, Inc. (-10.64), greater than Aldeyra Therapeutics, Inc. (-9.62), less than Gamida Cell Ltd. (-0.23), greater than Checkpoint Therapeutics, Inc. (-1.81), greater than Candel Therapeutics, Inc. (-3.67), greater than BioRestorative Therapies, Inc. (-2.41), greater than XTL Biopharmaceuticals Ltd. (-38.92), greater than Cingulate Inc. (-1.82), less than Adial Pharmaceuticals, Inc. (-0.34), less than TransCode Therapeutics, Inc. (-0.10), less than Aditxt, Inc. (-0.02), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than Avenue Therapeutics, Inc. (-0.31), greater than BiondVax Pharmaceuticals Ltd. (-2.29), greater than Oramed Pharmaceuticals Inc. (-15.30), greater than MediWound Ltd. (-7.71), greater than BioLineRx Ltd. (-1.63),
Company | PE Ratio | Market cap |
---|---|---|
-7.70 | $31.25M | |
-17.19 | $163.85M | |
-0.76 | $14.97M | |
-3.36 | $58.65M | |
-4.99 | $73.54M | |
-10.64 | $252.08M | |
-9.62 | $364.25M | |
-0.23 | $4.34M | |
-1.81 | $93.07M | |
-3.67 | $197.00M | |
-2.41 | $10.59M | |
-38.92 | $14.71M | |
-1.82 | $12.90M | |
-0.34 | $6.40M | |
-0.10 | $4.56M | |
-0.02 | $1.68M | |
-1.10 | $44.68M | |
-0.31 | $4.05M | |
-2.29 | $4.97M | |
-15.30 | $95.81M | |
-7.71 | $179.05M | |
-1.63 | $55.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Can-Fite BioPharma Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Can-Fite BioPharma Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Can-Fite BioPharma Ltd.'s PE Ratio?
How is the PE Ratio calculated for Can-Fite BioPharma Ltd. (CANF)?
What is the highest PE Ratio for Can-Fite BioPharma Ltd. (CANF)?
What is the 3-year average PE Ratio for Can-Fite BioPharma Ltd. (CANF)?
What is the 5-year average PE Ratio for Can-Fite BioPharma Ltd. (CANF)?
How does the current PE Ratio for Can-Fite BioPharma Ltd. (CANF) compare to its historical average?